HUP0301691A3 - Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use - Google Patents

Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use

Info

Publication number
HUP0301691A3
HUP0301691A3 HU0301691A HUP0301691A HUP0301691A3 HU P0301691 A3 HUP0301691 A3 HU P0301691A3 HU 0301691 A HU0301691 A HU 0301691A HU P0301691 A HUP0301691 A HU P0301691A HU P0301691 A3 HUP0301691 A3 HU P0301691A3
Authority
HU
Hungary
Prior art keywords
tipe
isoforms
cloning
expression
methods
Prior art date
Application number
HU0301691A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HUP0301691A2 publication Critical patent/HUP0301691A2/hu
Publication of HUP0301691A3 publication Critical patent/HUP0301691A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
HU0301691A 2000-04-03 2001-03-26 Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use HUP0301691A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19431800P 2000-04-03 2000-04-03
US09/817,676 US6800470B2 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
PCT/US2001/009664 WO2001074837A1 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Publications (2)

Publication Number Publication Date
HUP0301691A2 HUP0301691A2 (hu) 2003-08-28
HUP0301691A3 true HUP0301691A3 (en) 2005-04-28

Family

ID=26889896

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301691A HUP0301691A3 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use

Country Status (9)

Country Link
US (4) US6800470B2 (enExample)
JP (1) JP4584525B2 (enExample)
KR (1) KR20020093017A (enExample)
AU (1) AU5100201A (enExample)
CA (1) CA2404965A1 (enExample)
DK (1) DK1268509T3 (enExample)
HU (1) HUP0301691A3 (enExample)
MX (1) MXPA02009781A (enExample)
WO (1) WO2001074837A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301691A3 (en) * 2000-04-03 2005-04-28 Sankyo Co Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
JP2006514828A (ja) * 2002-10-14 2006-05-18 メドベット・サイエンス・プロプライエタリー・リミテッド スフィンゴシンキナーゼの機能的レベルを調節することによって上皮細胞活性を調節する方法
WO2004061107A1 (ja) * 2002-12-27 2004-07-22 The New Industry Research Organization スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
CA2329124A1 (en) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
AU3828301A (en) * 2000-02-14 2001-08-27 Curagen Corp Novel sphingosine kinases
HUP0301691A3 (en) * 2000-04-03 2005-04-28 Sankyo Co Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use

Also Published As

Publication number Publication date
KR20020093017A (ko) 2002-12-12
DK1268509T3 (da) 2010-03-08
US20120107833A1 (en) 2012-05-03
WO2001074837A1 (en) 2001-10-11
JP2004500117A (ja) 2004-01-08
US20040203104A1 (en) 2004-10-14
US6800470B2 (en) 2004-10-05
JP4584525B2 (ja) 2010-11-24
HUP0301691A2 (hu) 2003-08-28
US20090169555A1 (en) 2009-07-02
AU5100201A (en) 2001-10-15
US7419814B2 (en) 2008-09-02
CA2404965A1 (en) 2001-10-11
US7803595B2 (en) 2010-09-28
US8263349B2 (en) 2012-09-11
US20020042101A1 (en) 2002-04-11
MXPA02009781A (es) 2004-09-06

Similar Documents

Publication Publication Date Title
IL133672A0 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1346606A4 (en) AEROSOL GENERATOR WITH SEVERAL HEATING ZONES AND METHOD FOR USE THEREOF
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
IL162328A0 (en) Adjustable chair and method of use
AU1194802A (en) DNA expression vectors and methods of use
AU7334901A (en) Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
SI0736525T1 (en) Benzonitriles as 5-HT agonists and antagonists
GB2327190B (en) Process for the preparation of depilatory compositions and their use
HUP0104550A3 (en) Creamy laundry composition production and use thereof
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
AU5100201A (en) Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods ofuse thereof
HUP0103444A3 (en) Composition for the protection of keratinous fibers containing ceramides and/or glycoceramides
HUP0501056A2 (en) Use of cationic surface active agents and fiber softening compositions containing the same
PL360289A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
PL351301A1 (en) Novel inhibitors of metaloprotease, methods of obtaining them and pharmacological composition containing such inhibitors
EP1352637A4 (en) HAIRCARDANTS AND COMPOSITIONS COMPRISING THEM
HUP0200162A3 (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
HU0000039D0 (en) Use of cationic monobenzene nitroanalines in the dyeing of keratinous fibres, dyeing composition and dyeing processes
AU2233095A (en) Cloning and expression of human gmp synthetase, its use in screening for inhibitors of human gmp synthetase and inhibitors of human gmp synthetase
IL147103A0 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
ZA975793B (en) Isolation of cloning of the human harsa-l gene and uses thereof
GB9718808D0 (en) Cloning and expression of 5-HT receptor